Foralumab TZLS-401 50 µg
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Active Secondary Progressive Multiple Sclerosis
Conditions
Non-Active Secondary Progressive Multiple Sclerosis
Trial Timeline
— → —
NCT ID
NCT06802328About Foralumab TZLS-401 50 µg
Foralumab TZLS-401 50 µg is a pre-clinical stage product being developed by Tiziana Life Sciences for Non-Active Secondary Progressive Multiple Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT06802328. Target conditions include Non-Active Secondary Progressive Multiple Sclerosis.
Hype Score Breakdown
Clinical
3
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06802328 | Pre-clinical | Active |
Competing Products
1 competing product in Non-Active Secondary Progressive Multiple Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Foralumab TZLS-401 100 µg | Tiziana Life Sciences | Phase 2 | 32 |